Pancreas
- (101-21) A Phase 1 Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic,
Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients
with Advanced Solid Tumors
-
(131-17) A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (IT-01) (Phase 1 clinical trial, appropriate for patients with all solid tumors.)
-
(138-20) Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus
Standard-of-Care Chemotherapy for First and Second Line Treatment of Locally
Advanced or Metastatic Pancreatic Cancer (Phase 2 clinical trial, appropriate for patients with pancreatic cancer.)
-
(155-17) 0C 17-1: Phase 1 Multi-center Study of the Safety Pharmacokinetics
and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors
and C-Met Dysregulation (Phase 1 clinical trial, appropriate for patients with advanced solid
malignancies.)
-
(157-17) FID-007 in Treating Participants With Advanced Solid Tumors (Phase 1 clinical trial, appropriate for patients with advanced solid
malignancies.)
-
(168-18) Trial to Evaluate Safety and Tolerability of GP-2250 in Combination
With Gemcitabine (Phase 1/2 clinical trial, appropriate for patients with pancreatic cancer.)
-
(187-17) Trial of ZW25 in Patients With Advanced HER2-expressing Cancers(Phase 1 clinical trial, appropriate for patients with HER2-expressing cancers.)
-
(188-18) A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors (Phase 1 clinical trial, appropriate for patients with advanced solid tumors.)
-
(205-19) Study to Assess AFM24 in Advanced Solid Cancers (Phase 1/2a clinical trial, appropriate for patients with advanced solid tumors.)
-
(221-19) Study of GNX102 in Patients With Advanced Solid Tumors (Phase 1 clinical trial, appropriate for patients with advanced solid tumors.)
Certain clinical trials may not be listed on ClinicalTrials.gov. To learn
more about these or other clinical trials, please call 949-764-5543 or
contact us online.